Loading...
•
Jun 30
Alvotech Q2 2025 Earnings Report
Alvotech posted a strong second quarter with $173.2 million in total revenue and $32 million in net income, continuing its positive cash flow momentum.
Key Takeaways
Alvotech delivered robust Q2 2025 results, highlighted by growth across biosimilar products and global expansion. The company generated $173.2 million in revenue and $32 million in net income. Product launches and cost management contributed to improved profitability and cash performance.
Total revenue for Q2 reached $173.2 million, driven by product and license income.
Net income totaled $32 million, following a strong Q1 performance.
EPS came in at $0.11 with adjusted EPS at $0.14.
Q2 marked the second consecutive quarter of positive operating cash flow.
Alvotech
Alvotech
Alvotech Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comLicense and Other Revenue
CapyFin.comOther Income Revenue
CapyFin.com Forward Guidance
Alvotech maintained its guidance for FY 2025, projecting $600–700 million in revenue and $200–280 million in adjusted EBITDA, driven by continued product rollout and global expansion.
Positive Outlook
- Full-year revenue guidance reaffirmed at $600–700 million.
- Adjusted EBITDA expected to reach $200–280 million.
- Strong demand for biosimilars in key markets.
- New commercial partnerships established in Q2.
- Continued improvement in cash flow from operations.
Challenges Ahead
- License revenue declined YoY due to milestone timing.
- Exchange rate fluctuations impacted income.
- Q2 operating margin was lower than Q1.
- R&D expenses increased due to clinical program investments.
- Ongoing legal and listing-related G&A costs remained elevated.